{
    "id": 25737,
    "fullName": "FADD over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FADD over exp indicates an over expression of the Fadd protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 8772,
        "geneSymbol": "FADD",
        "terms": [
            "FADD",
            "GIG3",
            "MORT1"
        ]
    },
    "variant": "over exp",
    "createDate": "11/14/2016",
    "updateDate": "11/14/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9218,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TL32711 (birinapant) combined with radiotherapy, which induced TNF-alpha, led to increased sensitivity in a head and neck squamous cell carcinoma cell line xenograft model positive for BIRC2 and over expressing FADD, demonstrating complete tumor regression (PMID: 27469115).",
            "molecularProfile": {
                "id": 26783,
                "profileName": "BIRC2 pos FADD over exp"
            },
            "therapy": {
                "id": 4953,
                "therapyName": "Birinapant + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9215,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells positive for BIRC2 and over expressing FADD demonstrated sensitivity to treatment with TL32711 (birinapant) with or without TNF-alpha, resulting in increased cell death and cell-cycle arrest in culture (PMID: 27469115).",
            "molecularProfile": {
                "id": 26783,
                "profileName": "BIRC2 pos FADD over exp"
            },
            "therapy": {
                "id": 2647,
                "therapyName": "Birinapant",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9219,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TL32711 (Birinapant) combined with radiotherapy resulted in suppression of tumor growth in a head and neck squamous cell carcinoma cell line xenograft model over expressing FADD and BIRC2 (PMID: 27469115).",
            "molecularProfile": {
                "id": 26786,
                "profileName": "BIRC2 over exp FADD over exp"
            },
            "therapy": {
                "id": 4953,
                "therapyName": "Birinapant + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7034,
                    "pubMedId": 27469115,
                    "title": "SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27469115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26777,
            "profileName": "FADD over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26783,
            "profileName": "BIRC2 pos FADD over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26786,
            "profileName": "BIRC2 over exp FADD over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}